The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

January 10, 2019

Understanding Immunotherapy

Dr Morganna Freeman breaks down her methods for explaining immunotherapy to her patients.

July 17, 2018

How Molecular Biomarkers Have Impacted Cancer Treatment

Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges and opportunities of precision medicine and molecular biomarkers in their clinical practice from an oncologist’s and a pathologist’s perspective.